ReShape Lifesciences (Formally known as EnteroMedics)

263 articles with ReShape Lifesciences (Formally known as EnteroMedics)

• 

  Year-End Research Advances Approaches, Both Genetic and Device-Oriented, to T...

  12/27/2018

  Researchers at the University of Wisconsin-Madison have developed a battery-free, easily implantable device, about a third the size of a penny, that helped laboratory rats lose weight.

• Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line

  12/18/2018

  Apollo Endosurgery, Inc., today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable gastric banding system and other accessories used in laparoscopic bariatric surgery, to ReShape Lifesciences Inc.

• ReShape Lifesciences Announces European Trial to Support CE-Mark of ReShape Vest

  7/31/2018

  ReShape Lifesciences Inc. announced the Company has commenced site initiation training for the first clinical trial site that will participate in the multi-center trial of the ReShape VestTM to support CE Mark approval.

• ReShape Lifesciences Announces $2.7 Million Registered Direct Offering Priced At-the-Market

  7/11/2018

  ReShape Lifesciences Inc. (Nasdaq:RSLS), today announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,241,382 shares of its common stock.

• ReShape Lifesciences Expands Intra-gastric Balloon Business to Include Brigham and Women's Hospital in Boston

  7/10/2018

  ReShape Lifesciences Inc. announced the successful implant of the first ReShape Balloon™ at the Brigham and Women's Hospital in Boston, MA.

• ReShape Lifesciences Announces Acceptance of Abstract to be Presented at IFSO Annual Conference

  6/27/2018

  The company has had an abstract accepted by the scientific committee of the 23rd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).

• ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest

  6/19/2018

  ReShape Lifesciences Inc. announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity,"

• ReShape Lifesciences Announces $1.5 Million Registered Direct Offering Priced At-the-Market

  6/7/2018

  ReShape Lifesciences Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 374,572 shares of its common stock, at a purchase price per share of $3.92

• ReShape Lifesciences Assembles World Class Scientific Advisory Board

  6/6/2018

  ReShape Lifesciences Inc. announced the formation of the Company's Scientific Advisory Board (SAB)

• ReShape Lifesciences Announces New Patent Grant Expanding its Bioelectronic and Neuromodulation Portfolio

  6/5/2018

  Patent is directed to a combination of blocking and stimulating the vagus and celiac nerve branches using specific bioelectronic parameters to treat gastrointestinal disorders, including obesity, diabetes, and various combinations thereof.

• ReShape Lifesciences Provides Update on FDA Letter to Health Care Providers Related to Intragastric Balloons

  6/4/2018

  ReShape Lifesciences Inc. provided an explanation and clarifying details to a letter dated June 4, 2018 that the U.S. Food and Drug Administration (FDA) posted on their website addressed to Health Care Providers.

• ReShape Lifesciences Announces 1-for-15 Reverse Stock Split

  6/1/2018

  ReShape Lifesciences Inc. announced that its Board of Directors has declared a 1-for-15 reverse stock split of the company's common stock

• ReShape Lifesciences to Participate at Digestive Disease Week 2018

  5/24/2018

  ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the company will be exhibiting and participating at Digestive Disease Week (DDW), which is taking place from June 2-5, 2018 at the Walter E. Washington Convention Center in Washington, DC.

• ReShape Lifesciences Announces Submission for Approval of ReShape Balloon™ in Canada

  5/10/2018

  ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the submission of an application to the Medical Devices Bureau of the Therapeutic Products Directorate in Canada that seeks to amend the Company's existing Canadian medical device license to include distribution of the Company's current generation ReShape Balloon™ and associated accessories.

• ReShape Lifesciences to Host First Quarter 2018 Conference Call on May 14, 2018

  4/30/2018

  ReShape Lifesciences Inc. announced that it will host a conference call to discuss financial results for the first quarter 2018 on Monday, May 14, 2018 at 1:30 PM Pacific Time.

• ReShape Lifesciences Continues to Grow Presence in Middle East with Distribution in Bahrain

  4/24/2018

  ReShape Lifesciences Inc. announced that the ReShape Balloon™ was granted registration by the National Health Regulation Authority (NHRA) in the Kingdom of Bahrain.

• Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018

  4/18/2018

  ReShape Lifesciences Inc. announced that over 40 surgeons were trained to implant the ReShape BalloonTM during the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2018 /16th World Congress that was held in Seattle from April 11-14, 2018.

• ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes

  4/10/2018

  Results Showing Improved Glycemic Control with ReShape Lifesciences Neuromodulation in an Obese Rat Model to be Presented at Industry Conference

• ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia

  4/3/2018

  Initial Stocking Order Received from Dar Al Zahrawi Medical Co LLC, KSA

• ReShape Lifesciences Announces $6 Million Registered Direct Offering

  4/2/2018

  ReShape has entered into a securities purchase agreement with an institutional investor providing for the purchase and sale in a registered direct offering of shares of series D convertible preferred stock and a warrant to purchase shares of common stock for a purchase price of $6.0 million.